Sign up to save your podcasts
Or
Share Prostate cancer: Which mCSPC patients benefit from early treatment intensification? Case-based discussion
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Prostate cancer: Which mCSPC patients benefit from early treatment intensification? Case-based discussion
Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU CONNECT podcast.
The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for all patients and discuss the patient subgroups that benefit the most from early treatment intensification.
A number of patient scenarios are considered alongside the efficacy of the novel hormonal combinations, adverse event profiles, drug to drug interactions, volume of disease, age, comorbidities and patient risk.
View all episodes
By COR2ED Medical EducationAssoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU CONNECT podcast.
The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for all patients and discuss the patient subgroups that benefit the most from early treatment intensification.
A number of patient scenarios are considered alongside the efficacy of the novel hormonal combinations, adverse event profiles, drug to drug interactions, volume of disease, age, comorbidities and patient risk.